Useful resources |
Rofecoxib for rheumatoid arthritis (Cochrane Review) ABSTRACT Background: Editor's note: The anti-inflammatory drug rofecoxib (Vioxx) was withdrawn from the market at the end of September 2004 after it was shown that long-term use (greater than 18 months) could increase the risk of heart attack and stroke. Further informat . . . |
Full article: The full article is available on Wiley InterScience at http://www.thecochranelibrary.com |